Kornimate/medical-research-clean huggingface dataset:
stroke recovery initiative - registry for stroke research studies

Conditions: Stroke; Acute Stroke; Ischemic Stroke; Hemorrhagic Stroke; Subarachnoid Hemorrhage; Cerebral Ischemia; Cerebral Infarction; Cerebral Stroke; Cerebral Vascular Accident

Summary: the stroke recovery initiative is a nation-wide participant recruitment registry that connects people who have had a stroke with researchers who are working to develop new approaches to improve recovery after stroke.

the stroke recovery initiative at ucsf is designed to help people who have had a stroke to connect with researchers who are applying the latest science and technology to develop new treatments for stroke recovery. anyone who is 18 years of age or older and has had a stroke may submit a survey to join. the self-reported information on the survey will be used to match participants to current or future stroke research studies and study personnel for each specific study may contact participants for further screening. some studies are recruiting participants nationally, not just in the san francisco bay area.

Eligibility criteria:
* 18 years of age or older * have suffered a stroke * have ongoing symptoms as a result of the stroke

Keywords: stroke acute stroke ischemic stroke hemorrhagic stroke cerebral ischemia cerebral infarction cerebral stroke cerebral vascular accident stroke recovery
evaluation of subclinical coronary atherosclerosis for risk stratification using coronary computed tomography (ct) angiography

Conditions: Coronary Atherosclerosis

Summary: to evaluate the prognostic value of coronary ct angiography (ccta) for risk stratification in asymptomatic adults in comparison with conventional risk stratification (crs) and coronary artery calcium scoring (cacs).

the risk stratification of cardiovascular disease (cvd) in asymptomatic individuals represents a major challenge. for this purpose, a lot of risk prediction models that take demographic and clinical characteristics into account have been developed. although framingham risk score (frs) is most widely used among multiplr risk prediction models, it has some limitation for prediction of cvd especially in young adult and women. recently, coronary artery calcium score (cacs) has known to be powerful screening method for cvd, however, it cannot detect the noncalcified coronary plaques (ncp), so it does not represent the entire spectrum of atherosclerotic plaques and it also cannot evaluate the degree of stenosis. on the contrary, coronary ct angiography (ccta)can provide detailed coronary artery anatomy and plaque imaging about the location, burden and characteristics of atherosclerotic plaque per se, which might give additional insight to stratify the risk of future cardiac events and therapy. in this study, we will evaluate the prevalence and characteristics of subclinical coronary atherosclerosis on ccta in asymptomatic population. and we will investiage the follow up data for major cardiac adverse event such as cardiac death, nonfatal myocardial infarction, unstable angina and revascularization. therefore, we will finally evaluate the prognostic value of ccta for risk stratification in asymptomatic adults in comparsion with conventional risk stratification such as frs and cacs.

Eligibility criteria:
inclusion criteria: * asymptomatic subjects * adults \> 20 years * subjects who underwent both calcium score and coronary ct angiography exclusion criteria: * typical or atypical chest pain * subjects who underwent previous percutaneous coronary intervention * serious comorbid conditions(i.e. malignancy) * insufficient medical record * poor image quality

Keywords: coronary atheroslcerosis computed tomography
effectiveness of video-based multicomponent treatment for fibromyalgia plus face-to-face sesions in nature or at sea

Conditions: Fibromyalgia

Summary: the aim of this study was to examine the effectiveness of a video-based multicomponent program: the fibrowalk virtual plus face-to-face sessions for patients with fibromyalgia (fm) in nature or at sea (fm) compared to fibrowalk virtual only.

this is a tree-arm rct focused on the safety and potential effectiveness of the multicomponent program virtual fibrowalk as coadjuvant of treatment-as- usual (tau) in comparation of the fibrowalk virtual plus face-to-face sessions in the nature or at sea. virtual fibrowalk combines multicomponent approach based on pain neuroscience education (pne), therapeutic exercise, cognitive behavioural therapy (cbt) and mindfulness training. face-to-face sessions added to virtual fibrowalk combines de same components than fibrowalk virtual and added 4 face-to-face sessions (1 per mounth) to resolve doubts and reinforce the main concepts of therapy in the nature or at sea. the main hypothesis is that improvement on functional impairment of patients with fibromyalgia can be achieved by the direct intervention on mechanisms such as kinesiophobia and fear avoidance

Eligibility criteria:
inclusion criteria: * adults from 18 to 75 years-old. 1990 american college of rheumatology (acr) classification criteria + the 2011 modified - - - acr diagnostic criteria for fibromyalgia * able to understand spanish and accept to participate in the study. exclusion criteria: * participating in concurrent or past rcts (previous year). * comorbidity with severe mental disorders (i.e. psychosis) or neurodegenerative diseases (i.e. alzheimer) that that would limit the ability of the patient to participate in the rct.

Keywords: fibromyalgia multicomponent treatment chronic pain pain neuroscience education therapeutic exercise cognitive behavioural therapy mindfulness randomized controlled trial virtual format
the effectiveness of palatal brushing on denture stomatitis

Conditions: Denture Stomatitis

Summary: denture stomatitis (ds) is an oral biofilm associated inflammatory disease of the palatal mucosa. it is the most prevalent oral disease and the main indicator of poor oral health among denture wearers, affecting one-third of all complete denture wearers. the etiology of ds is multifactorial, with documented role of mechanical trauma, bacteria and fungi. risk factors may include, poor oral hygiene and nocturnal use of dentures. however, the evidence is ambiguous, inconclusive and recurrence following routine antifungal therapy is common. the proposed study is a phase ii clinical trial to evaluate the efficacy of palatal brushing in reducing the colony forming unit (cfu) count and clinical inflammation. the assessment of change in cfu count and clinical inflammation will be carried out at baseline, 3 months and 6 months.


Eligibility criteria:
inclusion criteria: * age 18 years or older * wearing a maxillary and mandibular complete conventional denture * having moderate to severe signs of denture stomatitis according to schwartz index * providing consent prior to study. exclusion criteria: * oral mucosal lesions other than denture stomatitis. * systemic conditions which predispose to candida specie infection such as uncontrolled diabetes and xerostomia. * history of chemotherapy/radiotherapy. * used antibiotics, steroidal or antifungal agents in the 4 weeks prior to the study. * scheduled to replace existing dentures with new ones during the length of the trial. * already using palatal brushing as a routine oral hygiene procedure.

Keywords: denture stomatitis denture erythematous stomatitis prosthesis stomatitis oral candidiasis palatal inflammation
clinical validation of medasense pain response index (pri)

Conditions: Surgery; Pain

Summary: in our previous study, nct01631695, we proposed and clinically evaluated the medasense pain response index, pri, in anesthetized patients undergoing surgery. note: the name pri has been changed to nol (nociception level) index. the pri is based on a non-linear combination of several pain-related physiological parameters into a one unique index (0-100). in this study we aim to validate the performance of the pri by: 1. investigating the patient's pri response to surgical painful stimuli under different levels of analgesia: * investigating patient's pri response to surgical painful stimuli under two different levels of remifentanil target control infusion (tci) rates. * investigating patient's pri response to standardized painful stimulus (tetanic stimulus) with and without opioids. 2. investigating the effect of beta-blockers on pri performance in patients taking chronic beta-blocker treatment. the study is based on recording and analyzing the subject's physiological signals, while recording painful events, medication dosing and different clinical signs.

pain is an unpleasant sensation, ranging from slight discomfort to intense suffering. since pain is a subjective phenomenon, it has frequently defied objective, quantitative measurements. today, in order to measure pain, subjective uni-dimensional scales are used to quantify pain. one of the most common scale used to rate a patient's pain intensity is the numeric pain scale (nps), usually scored from 0 to 100. hitherto, those scales are based on the subjective evaluation of pain by the patient. during anesthesia the patient cannot communicate and therefore the verbal or other report is impossible. as a consequence, due to misrepresentation of the existence or extent of pain, care providers may fail to estimate the correct measure of pain and give too much or too little medication, leading to possible complications and adverse reactions. a validated scoring system of subject's pain level, or as in the case of an anaesthetised patient, subject's nociception level, is therefore needed. in this study the investigators intend to test and analyze the performances of medasense pain response index, pri, by comparing it with other standard pain related indicators (heart rate (hr), heart rate variability (hrv), skin conductance, etc) before and after painful stimuli at different levels of analgesia. in addition, in order to reduce the variability between stimuli, a standardized stimulus (tetanic ,30 sec, 100hz, 60ma) will be given to all patients after sleep induction and before intubation, with and without administration of fentanyl and the values of the pri during these stimuli will be investigated.

Eligibility criteria:
inclusion criteria: * asa physical status 1-3 * elective surgery exclusion criteria: * pregnancy or lactation * history of severe cardiac arrhythmias * abuse of alcohol or illicit drugs * history of mental retardation, dementia, psychiatric disorders * allergy to any of the drugs to be used during anesthesia and recovery

Keywords: nociception analgesia intraoperative monitoring
effect of body mass on filgrastim pharmacokinetics

Conditions: Hematological Malignancy; Neutropenia

Summary: studies have shown that different percentages of body fat can alter the way drugs are distributed in the body. this study will use blood samples taken at different time points for patients taking neupogen to determine if higher body weights affect drug exposure. the information gathered from this study will help understand if patients with higher body weights need a different dosing plan. patients in this study will have blood draws once before they take neupogen and 6 times after they take the neuopen (for a total of 24 hours). these patients will be in the hospital already and will not need to make additional trips back to have blood drawn. a total of about 5-6 tablespoons of blood will be drawn for this study. 15 obese patients and 15 matched, non-obese patients will be enrolled into this study.


Eligibility criteria:
inclusion criteria: * age greater than or equal to 18 years * receiving filgrastim at 5mcg/kg ± 10% * admitted as an inpatient with an expected stay of at least 24 hours * weight is \> 190% of their ideal body weight (ibw) for "obese" patients or within 80 - 124% of ibw for matched control patients. * patient or their legally authorized representative understands and voluntarily signs the written informed consent prior to any study-specific procedures. a copy of the signed informed consent form will be retained by the treating institution. exclusion criteria: * patients who have received filgrastim within 24 hours prior to enrollment * patients who have received pegfilgrastim within 14 days prior to enrollment * hypersensitivity reaction to filgrastim or any related product * patients who have taken lithium within 7 days of enrollment * serum creatinine \> 1.5 mg/dl * patients who are pregnant or breastfeeding * patients who are unable to understand and/or render informed consent

Keywords: filgrastim obese non-obese pharmacokinetics
safety and efficiency of γδ t cell against lung cancer

Conditions: Lung Cancer

Summary: in this study, effects of γδt cells on human lung cancer in combination with tumor reducing surgery, for example, cryosurgery going to be investigated

lung tumor will be removed using tumor reducing surgery such as cryosurgery. pbmc of the patient will be separated from peripheral blood. after making them potential cancer killer γδ t cell and dc-cik, they will be infused to the patients as an immunotherapy treatment. note: originally, our designed proposal was to use autologous pbmcs from cancer patients to ex vivo expand vγ9vδ2-t cells, and then perform adoptive transfer therapy. however, pbmcs of majority of cancer patients could not be effectively expanded, including cell number, cell purity and cell function could not meet the requirements of reinfusion. meanwhile, those patients could not tolerate 100ml of blood drawing for culture every 2 \~ 3 weeks. therefore, we submitted new clinical study application to the ethical committee of the fuda hospital affiliated with jinan university (guangzhou, pr. china) by changing the autologous protocol with the allogeneic protocol. after the allogeneic protocol was approved, we adapted allogeneic cells instead of autologous in our subsequentially clinical study.

Eligibility criteria:
inclusion criteria: age: 18-75 karnofsky performance status \>50 diagnosis with lung cancer based on histology or the current accepted radiological measures classification tumor,nodes,metastasis-classification(tnm) stage: ⅱ,ⅲ,ⅳ will receive cryosurgery, ire, gd t cells life expectancy: greater than 3 months ability to understand the study protocol and a willingness to sign a written informed consent document exclusion criteria: patients with other kinds of cancer history of coagulation disorders or anemia patients with heart disease

Keywords: immunotherapy, γδ t cell, lung cancer
tele-physiotherapy on post-stroke hemiplegia patients

Conditions: Hemiplegia; Muscle Spasticity

Summary: the present preliminary randomized trial will be performed to compare the effectiveness of telephyisiotherapy plus physical exercises versus other conventional techniques (electromyographic biofeedback or conventional physiotherapy). participants will be chosen from hospital sagrado corazón de málaga, after the approval of the centre. one hundred and twenty patients with hemiplegia as a consequence of an ischaemic stroke will take part in the study. selection criteria included to be older than 65 years, with two months of evolution after the stroke and with the left paretic side. in addition, they had to have a positive diagnosis of covid-19. positive cases will be confirmed by pcr. due to the local sanitary regulations, all patients may require home confinement during 1 month without possibility to continue their rehabilitation program. physiological interventions started 20 days after the first negative pcr test. participants will be randomize in three different intervention groups, conventional therapy (n=40), carried out in the hospital, biofeedback therapy (n=40), also conducted in the hospital, and telephyisiotherapy (tp) plus physical activity (n=40). the intervention period will last for three months, and participants will be re-evaluated 30 days later to confirm treatment effectiveness. measurements electromyographic activity and hand strength the mean electromyographic (emg) activity will be determined with the neurotrans myoplus 2 pro system (verity medical ltd, uk), the same instrument used to carry out the intervention. the isometric strength (nw) of the hand will be assessed with a hand-held digital dynamometer (smedley digital hand dynamometer, rms ltd., uk). functional tests in the present work, the fugl-meyer will be used to determine the functional status of patients with stroke. the patients with better functionality had superior scores. in addition, the ability of the patients to perform basic daily living activities was determined through the barthel index. considering the advanced age of the participants, three extra-scales will be determined: the frail scale, the short physical performance battery (sppb) and the strength, assistance in walking, rise from a chair, climb stairs and falls (sarc-f) scale will be evaluated.


Eligibility criteria:
inclusion criteria: * patients with hemiplegia as a consequence of an ischaemic stroke * to be older than 65 years * voluntarily participate in the study exclusion criteria: * to suffer from dementia or severe cognitive decline * to have any specific contraindication for sport practice (as suffering from joint pain, etc.) * those with any diagnosis of severe pathology (cancer, cardiovascular event, etc.) during the study period.

Keywords: hemiplegia stroke telephyisiotherapy older adults
linezolid for the treatment of infections caused by methicillin resistant staphylococcus aureus in japan

Conditions: Infections, Nosocomial

Summary: use of linezolid in patients with methicillin-resistant staphylococcus aureus infections in japan


Eligibility criteria:
inclusion criteria: * infection due to methicillin-resistant staphylococcus aureus exclusion criteria: * hypersensitivity to linezolid
smart brain health in african-americans

Conditions: Opioid Use Disorder; Substance Use Disorders; Dopamine Dysregulation Syndrome; African Americans

Summary: the investigators hypothesize that opioid use in african-americans will be associated with hypodopaminergic alleles that alter the threshold for activating feelings of reward and pleasure within the dopaminergic system, and that these allelic frequencies will differ significantly from european americans. planned is a targeted system to study genetic risks for reward deficiency using risk gene panel to assign a genetic addiction risk score (gars), comprehensive surveys to determine quality of life and exposure to stressors and trauma. this system will allow prediction of addiction and relapse potential and delivery of personalized treatment.

individuals seeking treatment for opioid use disorder in the washington dc metro area will be recruited to this study, which consists of 1) early pre-disposition diagnosis using the genetic addiction risk score (gars); 2) assessment of reward deficiency, co-morbid neuropsychiatric disease, quality of life/happiness, stressors/trauma and other psychometric measurements using validated questionnaires; urine drug testing during actual treatment that uses comprehensive analysis of reported drugs to determine compliance with prescription medications and non-abstinence to illicit drugs; and 4) adjunctive treatment with neuroadaptogen amino acid therapy (naat), a glutaminergic-dopaminergic optimization nutraceutical (generic name: kb220) compared to placebo, aimed to prevent relapse by induction of dopamine homeostasis.

Eligibility criteria:
inclusion criteria: * must be able to consent and understand questions being asked during surveys * must be willing to undergo pharmacogenetic testing * must be able to swallow tablets exclusion criteria: * clinical diagnosis of alzheimer's disease/dementia * clinical diagnosis of schizophrenia * clinical diagnosis of a terminal disorder
predictive biomarkers for pediatric chronic graft-versus-host disease

Conditions: Chronic Graft vs Host Disease

Summary: chronic graft-versus-host disease (cgvhd) can be hard to diagnose, difficult to manage and contributes significantly to morbidity and mortality in hematopoietic stem cell transplantation patients. the research will look into identifying and validating cgvhd biological indicators (=bio-markers) which will be evaluated whether they can predict a future development of the disease. the study hypothesis is that a number of previously reported cgvhd bio-markers, known to be present at the time of cgvhd diagnosis, will also be present at earlier time points, before cgvhd develops. following validation, the bio-markers will be beneficial for finding those patients who are in higher risk to develop cgvhd. by identifying the higher-risk group, which is more likely to develop cgvhd, a pre-emptive therapy might be applied in order to prevent or reduce the prevalence of the disease.


Eligibility criteria:
inclusion criteria: 1. allogeneic hematopoietic stem cell transplantation for any malignant or non-malignant disease. 2. age 0-17.99 years at the time of transplantation. 3. bone marrow, peripheral blood stem cell and umbilical cord blood (including single or double cord blood) as the graft source. 4. any conditioning regimen with any chemotherapy / radiation therapy combination. haploidentical donor transplants with post-transplant cyclophosphamide are also allowed. 5. use of serotherapy is permitted. 6. any graft-versus-host disease prophylaxis is permitted, including post-hsct cyclophosphamide. 7. if participant weighs between 0-20 kg, participant must be able to provide 15 ml of whole blood at each time point. 8. if participant weighs over 20 kg, participant must be able to provide 1ml/kg of whole blood, up to a maximum of 23 ml for the pre-conditioning sample and 32 ml for samples at day +100, 6-months, 12-months, +/- the cgvhd sample. 9. written informed consent from parents. 10. assent from study participant when appropriate. 11. participation on other clinical trials is acceptable. exclusion criteria: 1. autologous hsct. 2. patients referred to a bone marrow transplant (bmt) center from a non-bmt center, where it is anticipated (at the discretion of the center pi) that adequate follow up according to the rules of this protocol can not be met, including the requirement for a reassessment by the bmt center at the time of cgvhd diagnosis. 3. ex-vivo t-cell depletion of graft source (e.g. cd34 selection). 4. second (or greater) allogeneic transplants (first allogeneic transplant where a previous autologous transplant was performed is permitted). 5. syngeneic transplants.